Nexien BioPharma, Inc (OTC: NXEN) Developing a cannabinoid-based drug pipeline.

November 14, 2018 admin CEO Interview, Healthcare Comments Off on Nexien BioPharma, Inc (OTC: NXEN) Developing a cannabinoid-based drug pipeline.
Alex Wasyl, CEO Nexien BioPharma

 

Get our FREE Newsletter! Discover Stocks with +1,000% Upside Potential!
Join over 100,000 investors and business leaders worldwide. Discover the Next Super Stock before the rest of the crowd.
Your privacy is our priority. Your email address will never be sold or shared with anyone else.

 

 

Alex Wasyl, CEO Nexien BioPharma

 

 

 

 

 

 

Nexien BioPharma, Inc (OTC: NXEN) CEO Interview with Alex Wasyl discussing the company’s cannabinoid-based drug development pipeline. Drug development targets include, epliepsy, myotonia and other markets.




Related Articles

Healthcare

CytoDyn (OTC: CYDY) Anticipates Revenue Commencing in August 2019 from Use of PA-14 and/or PRO 140 in Diagnostic Test

July 1, 2019 admin Healthcare, Newsmakers Comments Off on CytoDyn (OTC: CYDY) Anticipates Revenue Commencing in August 2019 from Use of PA-14 and/or PRO 140 in Diagnostic Test

CytoDyn Signs Non-binding Agreement for Diagnostic Licenseand Supply Agreement with IncellDX for PA-14 and/or PRO 140 (non-commercial grade) Collaboration represents an immediate revenue opportunity as a diagnostic test for receptor occupancy and the existence of […]

Newsmakers

Yield Growth Application for new INCI name granted for Yield Growth’s (OTC: BOSQF) Cannabis Sativa Hemp Root Oil made with Patent Pending Technology

April 23, 2019 admin Newsmakers Comments Off on Yield Growth Application for new INCI name granted for Yield Growth’s (OTC: BOSQF) Cannabis Sativa Hemp Root Oil made with Patent Pending Technology

VANCOUVER, British Columbia, April 23, 2019  — The Yield Growth Corp. (CSE :BOSS) (OTC: BOSQF) (Frankfurt: YG3) announces it has been successful in its application to obtain an International Nomenclature Cosmetic Ingredient (INCI) name for its novel […]